We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 57 for:    COMPASS
Previous Study | Return to List | Next Study

COMPASS Trial: a Direct Aspiration First Pass Technique (COMPASS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02466893
Recruitment Status : Completed
First Posted : June 9, 2015
Last Update Posted : February 12, 2018
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Medical University of South Carolina

Brief Summary:
Intravenous (IV) tissue plasminogen activator (tPA) administration has been shown to be safe and effective for treatment of AIS within 3 hours of symptom onset, and newer evidence has shown potential benefit out to 4.5 hours. Mechanical thrombectomy for AIS patients has been shown in clinical trials to be safe up to 8 hours after symptom onset. Recent trials utilizing advanced imaging to identify patients with large vessel occlusions amenable to intra-arterial thrombectomy (IAT) have shown superiority endovascular therapy over medical therapy to result in improved patient functional outcomes. Pilot data utilizing the ADAPT approach has shown superior technical results with similar functional outcomes while lowering procedure time and device costs versus traditional stent retriever as a first line therapy approaches

Condition or disease Intervention/treatment Phase
Ischemic Cerebrovascular Accident Other: Adapt/Standard Stent Retriever (SR) Group Not Applicable

Detailed Description:

This is a prospective, randomized trial comparing mechanical thrombectomy with the ADAPT approach to stent retrievers in patients presenting with AIS within 6 hours of symptom onset. Any cleared mechanical stent retriever (SR) or aspiration catheter device that is in common use in the operator's region of practice is approved for use. Prior to releasing any sites to enroll patients, we will collect the following information on the most recent 20 acute ischemic stroke cases, at least five of which must have used direct aspiration as a first approach, and at least five of which must have used stent retrievers as a first approach. It is permissible to go back in time farther than the most recent 20 cases to fulfill either or both of these requirements. There is no requirement for the remaining 10 cases. The datapoints to be collected include:

  • Age
  • Gender
  • LVO location
  • Side of LVO
  • NIHSS at presentation
  • Time of onset
  • Time of hospital arrival
  • Time imaging completed
  • Time of groin puncture
  • Time of revascularization, if applicable
  • Time procedure terminated, if revascularization was not obtained
  • tPA given pre-procedure
  • Time of IV-tPA
  • Imaging type
  • Perfusion imaging
  • Devices used
  • Passes attempted
  • Device success
  • Standard and modified final TICI scores
  • Outcome measurements: incidence of post-op ICH, discharge and 90 day NIHSS, discharge and 90 day mRS, any and all complications Patients who meet the inclusion and exclusion criteria, consent to participate, and who are randomized will be considered enrolled. Treatment arm will be randomly assigned by a central web-based system in a 1:1 manner to treatment with either ADAPT or SR thrombectomy. Data on each patient will be collected at the time of enrollment and treatment, and at subsequent follow-up visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: COMPASS Trial: a Direct Aspiration First Pass Technique
Study Start Date : June 2015
Actual Primary Completion Date : July 2017
Actual Study Completion Date : February 2018

Arm Intervention/treatment
ADAPT Technique/Standard SR Group Other: Adapt/Standard Stent Retriever (SR) Group
If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.

Primary Outcome Measures :
  1. 90-day global disability assess via the modified Rankin Scale score (mRS) [ Time Frame: 2 years ]
    The primary objective is to show that AIS patients, with appropriate image selection, treated with ADAPT mechanical thrombectomy approach within 6 hours of symptom onset do not have inferior clinical outcomes to those treated with a first-line stent retriever approach with 90-day global disability assessed via the modified Rankin Scale score (mRS), analyzed using success criteria as mRS 0 to 2.

Secondary Outcome Measures :
  1. Cost effectiveness of ADAPT approach [ Time Frame: 2 years ]
    Demonstrate that the ADAPT approach is technically a superior and more cost effective approach than primary stent retriever use in the treatment of AIS.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 and older (i.e., candidates must have had their 18th birthday)
  2. NIHSS ≥8 at the time of neuroimaging
  3. Presenting or persistent symptoms within 6 hours of when groin puncture can be obtained
  4. Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation)
  5. The operator feels that the stroke can be appropriately treated with traditional endovascular approaches (the ADAPT approach or conventional first-line stent retriever approach)
  6. Pre-event Modified Rankin Scale score 0-1
  7. Non-contrast CT/CTA for trial eligibility performed or repeated at treating ADAPT stroke center.
  8. Consenting requirements met according to local IRB

Exclusion Criteria:

  1. Patient is more than 6-hours from symptom onset
  2. Rapidly improving neurologic examination
  3. Absence of large vessel occlusion on non-invasive imaging
  4. Presence of an existing or pre-existing large territory infarction
  5. Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory
  6. Absent femoral pulses
  7. Excessive vascular access tortuosity that will likely result in unstable access platform.
  8. Pregnancy; if a woman is of child-bearing potential a urine or serum beta HCG test is positive.
  9. Severe contrast allergy or absolute contraindication to iodinated contrast.
  10. Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.
  11. Patient has a severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.

Head CT or MRI Scan Exclusion Criteria

  • Presence of blood on imaging (subarachnoid hemorrhage (SAH)), intracerebral hemorrhage (ICH), etc.)
  • High density lesion consistent with hemorrhage of any degree
  • Significant mass effect with midline shift
  • Core infarct lesion volume >50 cc.
  • Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT scan or ASPECTS of < 7; Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02466893

Layout table for location information
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29461
Sponsors and Collaborators
Medical University of South Carolina
Icahn School of Medicine at Mount Sinai
Layout table for investigator information
Principal Investigator: Aquilla Turk, DO Medical University of South Carolina
  Study Documents (Full-Text)

Documents provided by Medical University of South Carolina:
Statistical Analysis Plan  [PDF] December 5, 2017

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT02466893    
Other Study ID Numbers: PRO00043325
First Posted: June 9, 2015    Key Record Dates
Last Update Posted: February 12, 2018
Last Verified: February 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemic Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases